 TAIPEI, Taiwan, Sept. 08, 2021 GLOBE NEWSWIRE -- Taiwan Liposome Company or TLC Nasdaq: TLC, TWO: 4152, the Company, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that it has notified Nasdaq that it will apply for the voluntary delisting of its American depositary shares ADSs from the Nasdaq Global Market. 